ClinicalTrials.gg

Mpox, Monkeypox clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 72 studies for Mpox, Monkeypox across more than 10 countries. 30 are recruiting or about to start. 61 of them are mainly about Mpox, Monkeypox (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-01.

Status

Completed
24
Recruiting
16
Active, not recruiting
11
Not yet recruiting
7
Enrolling by invitation
6
Terminated
3

Phase

Phase 2
12
Phase 3
9
Phase 1
8
Phase 4
4

Where

Democratic Republic of the Congo
19
United States
11
France
7
Spain
6
Belgium
4
United Kingdom
4

Who develops what

Add Mpox, Monkeypox to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 5 programs from 3 companies, 4 with this as their studies’ main aim; 0 with a live phase 3 study; 3 primary completions in the next 12 months. Compare Sinopharm, Bavarian Nordic and BioNTech here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
MVA-BN smallpox vaccineRecent, limitedPhase 4 trial recorded
Evidence
  • NCT07253675 · Sinopharm · Phase 2 · live · comparator · “MVA-BN” · registered Nov 2025
Bavarian Nordic88% of its industry studies11 study

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 5 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (3)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 30 Nov 2026 est.MVA-BN smallpox vaccine · Bavarian Nordic · Phase 2 main aimNCT07199569 Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production Cells — primary endpoint: Immunogenicity of 2 doses of MVA-BN · 970 enrolled
  • 28 Feb 2027 est.MVA-SIBP low dose · Sinopharm · Phase 2 main aimvs MVA-BN smallpox vaccineNCT07253675 Evaluate the Safety and Immunogenicity of the MVA-SIBP Vaccine in the Democratic Republic of the Congo — primary endpoint: Unsolicited adverse events · 180 enrolled
  • Jun 2027 est.BNT166A · BioNTech SE · Phase 2 main aimNCT07379580 A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine Candidate in Africa — primary endpoint: Number (and percentage) of participants with at least one solicited local reaction (pain, erythema/redness, induration/swelling) · 310 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

Coming up

15studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest

Who these studies take

Of the 16 Mpox, Monkeypox studies recruiting now, 13 (81%) set no upper age limit and 2 (13%) stop at 75 or younger. 6 (38%) take children under 18. 0 (0%) are for women only and 1 (6%) for men only; 6 (38%) take healthy volunteers.

Recruiting studies that take each age, of 16
AgeWomenMen
105 (31%)6 (38%)
1815 (94%)16 (100%)
3015 (94%)16 (100%)
4015 (94%)16 (100%)
5015 (94%)16 (100%)
6513 (81%)14 (88%)
7513 (81%)14 (88%)
8512 (75%)13 (81%)

Across all 72 studies, recruiting or not: 29% stop at 75 or younger and 28% at 65; 44% take children; 3% are for women only and 6% for men only; 53% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Mpox, Monkeypox studies take

Of 23 observational studies under Mpox, Monkeypox, half reached primary completion within 18 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Observational18 mo10–45 · 23 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

Studies

Recruiting first, then most recently updated. Showing 50 of 72. Browse all 72 → or search them.